M
Minerva Neurosciences, Inc. (NERV)
NCM – Real Time Price. Currency in USD
4.37
+0.26 (6.33%)
At close: Jun 26, 2026, 4:00 PM EDT
4.36
-0.01 (-0.23%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.37
+0.26 (6.33%)
At close: Jun 26, 2026, 4:00 PM EDT
4.36
-0.01 (-0.23%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
| Name | Position |
|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman, CEO & Member of Scientific Advisory Board |
| Mr. Frederick W. Ahlholm CPA | Senior VP, CFO & Secretary |
| Mr. James O'Connor | Chief Business Officer & General Counsel |
| Mr. Joseph Reilly | Senior VP & COO |
| Mr. William B. Boni | Vice President of Investor Relations & Corporate Communications |
| Prof. Michael Davidson M.D. | Member of Scientific Advisory Board & Chief Medical Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-04 | 8-K | d57321d8k.htm |
| 2026-05-27 | 8-K | d119518d8k.htm |
| 2026-05-05 | 8-K | d947378d8k.htm |
| 2026-05-05 | 10-Q | nerv-20260331.htm |
| 2026-04-23 | DEFA14A | d109656ddefa14a.htm |
| 2026-04-23 | DEF 14A | d113727ddef14a.htm |
| 2026-04-23 | ARS | d11443dars.pdf |
| 2026-04-10 | PRE 14A | d113727dpre14a.htm |
| 2026-04-06 | 8-K | d41477d8k.htm |
| 2026-04-02 | 8-K | d143634d8k.htm |